Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|December 24, 2016
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemiaGunnar Larfors, Fredrik Sandin, Johan Richter, et al.
European Journal of Haematology|July 28, 2023
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactionsGunnar Larfors, Per Andersson, Gérald Jesson, et al.
Journal of Radiological Protection : Official Journal of the Society for Radiological Protection|February 12, 2026
Cytokine use in the Hematopoietic Subsyndrome of Acute Radiation Syndrome (H-ARS): Implications for the role of cytokines in a mass casualty radiologic/nuclear (R/N) emergencyNick Dainiak, Makoto Akashi, Nelson Chao, et al.
Blood|April 24, 2010
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapyAnna Kreutzman, Vesa Juvonen, Veli Kairisto, et al.
Leukemia & Lymphoma|August 21, 2014
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinibLotta Ohm, Adam Lundqvist, Paul Dickman, et al.
Experimental Hematology|February 20, 2003
Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemiaSusanne Tornhamre, Leif Stenke, Anna Granzelius, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 26, 2025
SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?Fadi G Haddad, Elias Jabbour, Massimo Breccia, et al.
European Journal of Haematology|November 6, 2024
Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid LeukemiaEnoch Yi-Tung Chen, Torsten Dahlén, Leif Stenke, et al.
European Journal of Haematology|February 3, 2016
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalenceNiklas Gunnarsson, Fredrik Sandin, Martin Höglund, et al.
Applied Health Economics and Health Policy|June 7, 2019
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid LeukemiaCarsten Hirt, Sergio Iannazzo, Silvia Chiroli, et al.
Pageof 7